Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Researchers in Japan are preparing for a first human trial of induced pluripotent stem cells (iPSCs) in patients with Parkinson’s…
Articles by Magdalena Kegel
FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
The U.S. Food and Drug Administration (FDA) will not process Acorda Therapeutics‘Â marketing application for Inbrija (CVT-301), intended for the…
Lack of Granulin Proteins — Once Considered Villains — Might Contribute to Parkinson’s, Study Suggests
Brain proteins called granulins — previously thought to be toxic — might play a crucial role in brain health, according…
Parkinson’s Might Be Driven by Autoimmune Processes, Researchers Say
Parkinson’s disease may in part be driven by autoimmune processes, according to researchers who discovered that certain immune cells react…
Biomarkers for Predicting Cognitive Decline in Parkinson’s Disease May Improve Future Clinical Trials
A range of biomarkers may help physicians predict which Parkinson’s disease patients will develop cognitive decline in the early years…
ATCC and Michael J. Fox Foundation Teamed Up to Discuss Parkinson’s Research Tools
Experts from ATCC — a leading nonprofit repository of biological materials — partnered with the Michael J. Fox…
First Dose Group in Parkinson’s Stem Cell Trial Successfully Transplanted
The fourth and last patient of the first group in a clinical trial of stem cell transplants in Parkinson’s disease…
Flexilev Microtablets May Help to Treat Parkinson’s for Some Patients
Flexilev microtablets containing both levodopa/carbidopa, used with an automatic dose dispenser, seemed to improve self-reported symptom control in some patients with…
Varying Thresholds for Parkinson’s Protein Toxicity Form Basis of New Disease Theory
Researchers at two world-renowned institutions have presented a new theory of how Parkinson’s disease (PD) and its symptoms develop— challenging…
NeuroDerm Reports Promising Phase 2 Results of Continuous Infusion Therapy for Parkinson’s Disease
NeuroDerm’s Phase 2 Parkinson’s disease (PD) trial of ND0612H — a continuous infusion of levodopa and carbidopa delivered…